• Publications
  • Influence
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
BACKGROUND First-line bevacizumab combined with chemotherapy significantly improves efficacy versus chemotherapy alone in human epidermal growth factor receptor 2 (HER2)-negative locally recurrent orExpand
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
AIM To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS Randomized patients receivedExpand
Adjuvant clodronate therapy in patients with locally advanced breast cancer--long term results of a double blind randomized trial. Slovak Clodronate Collaborative Group.
Between March 1990 and May 1993 seventy three patients with previously untreated breast cancer, Stage III or IV without osseal metastases were randomized to sodium clodronate 1600 mg daily p.o.(arm AExpand
Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
The aim of this study was to determine efficacy and toxicity of TIP combination (paclitaxel, ifosfamid, cisplatin) as first salvage treatment in patients with relapsed germ cell tumours (GCTs).Expand
Cancer control: strategies and priorities.
If current trends continue the incidence of cancer will rise in almost all areas of the world notably because of an increase in the mean age of the world population and a rise in tobacco consumption.Expand
National cancer control programs and setting priorities.
Although considerable resources are being allocated globally to cancer research, efforts to implement these findings efficiently are lagging behind. Enough is known about the cause of common tumorsExpand
Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The
4055 Background: Previous retrospective analyses of KRAS mutation status from the randomized CECOG/CORE 1.2.001 phase II trial has shown that treatment with cetuximab plus standard chemotherapy (CT)Expand
Determination of suramin in clinical samples using HPLC.
High-performance liquid chromatography (HPLC) was applied for the determination of suramin levels in serum samples from cancer patients treated with this drug. Ion-pair chromatography in combinationExpand
Phase II study of 4′-Epi-Doxorubicin in patients with untreated, extensive small Cell Lung Cancer
The purpose of the study was to investigate the antitumour activity and toxicity of high dose (120 mg m-2) single agent epirubicin therapy in untreated extensive small cell lung cancer patients. OutExpand